Schering-Plough’s Low AE Profile For Boceprevir Phase II Could Be Advantage Over Vertex’s Telaprevir In HCV Race

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".